Passive immunity with multi‐serotype heat‐killed Shigellae in neonatal mice

Barman, Soumik; Koley, Hemanta; Nag, Dhrubajyoti; Shinoda, Sumió; Nair, G. Balakrish; Takeda, Yoshifumi

doi:10.1111/1348-0421.12164

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inactivated ∆wzy Shigella flexneri 2a mutant which had O-antigen polysaccharide polymerase gene disrupted induced immunity cross-protective against serotypes 2a, 3a, and 6 in a mouse pulmonary model. 141 Heat killed multi-serotype Shigella (HKMS), which combined six Shigella serotypes (S. dysenteriae type 1, S. flexneri 2a, 3a, 6, S. sonnei, S. boydii), protected guinea pigs in a recto-colitis model, 142 neonatal mice passively, 143 and rabbits 144 against challenge of all six homologous strains.…”

Section: Inactivated Shigella Whole-cell Vaccine Candidatesmentioning

confidence: 99%

Vaccines against gastroenteritis, current progress and challenges

2020

View full text Add to dashboard Cite

Enteric viral and bacterial infections continue to be a leading cause of mortality and morbidity in young children in low-income and middle-income countries, the elderly, and immunocompromised individuals. Vaccines are considered an effective and practical preventive approach against the predominantly fecal-to-oral transmitted gastroenteritis particularly in the resource-limited countries or regions where implementation of sanitation systems and supply of safe drinking water are not quickly achievable. While vaccines are available for a few enteric pathogens including rotavirus and cholera, there are no vaccines licensed for many other enteric viral and bacterial pathogens. Challenges in enteric vaccine development include immunological heterogeneity among pathogen strains or isolates, a lack of animal challenge models to evaluate vaccine candidacy, undefined host immune correlates to protection, and a low protective efficacy among young children in endemic regions. In this article, we briefly updated the progress and challenges in vaccines and vaccine development for the leading enteric viral and bacterial pathogens including rotavirus, human calicivirus, Shigella, enterotoxigenic Escherichia coli (ETEC), cholera, nontyphoidal Salmonella, and Campylobacter, and introduced a novel epitope-and structurebased vaccinology platform known as MEFA (multiepitope fusion antigen) and the application of MEFA for developing broadly protective multivalent vaccines against heterogenous pathogens.

show abstract